SG11201604697TA - Membrane-penetrating peptides to enhance transfection and compositions and methods for using same - Google Patents

Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Info

Publication number
SG11201604697TA
SG11201604697TA SG11201604697TA SG11201604697TA SG11201604697TA SG 11201604697T A SG11201604697T A SG 11201604697TA SG 11201604697T A SG11201604697T A SG 11201604697TA SG 11201604697T A SG11201604697T A SG 11201604697TA SG 11201604697T A SG11201604697T A SG 11201604697TA
Authority
SG
Singapore
Prior art keywords
membrane
compositions
methods
same
penetrating peptides
Prior art date
Application number
SG11201604697TA
Other languages
English (en)
Inventor
Mollerat Du Jeu Xavier De
Original Assignee
Life Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies Corp filed Critical Life Technologies Corp
Publication of SG11201604697TA publication Critical patent/SG11201604697TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201604697TA 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same SG11201604697TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915429P 2013-12-12 2013-12-12
PCT/US2014/070176 WO2015089487A1 (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Publications (1)

Publication Number Publication Date
SG11201604697TA true SG11201604697TA (en) 2016-07-28

Family

ID=52273587

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201604697TA SG11201604697TA (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
SG10201811729PA SG10201811729PA (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201811729PA SG10201811729PA (en) 2013-12-12 2014-12-12 Membrane-penetrating peptides to enhance transfection and compositions and methods for using same

Country Status (11)

Country Link
US (5) US9856496B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP3079723B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP6912887B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102532559B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN106456793B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2014361806B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112016013516A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2933561A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2808866T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (2) SG11201604697TA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2015089487A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051089C (en) * 2012-05-02 2022-04-12 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
CN104583956B (zh) 2012-06-15 2019-01-04 英特尔公司 用于实现加载存储重新排序和优化的指令定义
CN104823168B (zh) 2012-06-15 2018-11-09 英特尔公司 用于实现从由加载存储重新排序和优化导致的推测性转发遗漏预测/错误中恢复的方法和系统
KR101996462B1 (ko) 2012-06-15 2019-07-04 인텔 코포레이션 명확화 없는 비순차 load store 큐
CN104583943B (zh) 2012-06-15 2018-06-08 英特尔公司 拥有具有分布式结构的动态分派窗口的虚拟加载存储队列
CN104823154B (zh) 2012-06-15 2017-12-29 英特尔公司 包括虚拟加载存储队列的处理器和系统
WO2013188306A1 (en) 2012-06-15 2013-12-19 Soft Machines, Inc. Reordered speculative instruction sequences with a disambiguation-free out of order load store queue
EP3079723B1 (en) 2013-12-12 2020-05-27 Life Technologies Corporation Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US20170016043A1 (en) 2015-07-13 2017-01-19 Life Technologies Corporation System and method for improved transient protein expression in cho cells
CN108779074A (zh) * 2016-03-01 2018-11-09 分子传递有限公司 植物病毒移动蛋白和其使用方法
EP3500585A4 (en) 2016-08-17 2020-04-01 Factor Bioscience Inc. NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION
US11414675B2 (en) * 2016-09-30 2022-08-16 Life Technologies Corporation Serum-free suspension system for lentiviral production
US11782050B2 (en) 2017-09-19 2023-10-10 Cannametrix, Llc Cell-based assay for quantifying the potency and efficacy of cannabinoids and/or terpenoids, and methods of use thereof
WO2019178479A1 (en) * 2018-03-16 2019-09-19 Sarepta Therapeutics, Inc. Chimeric peptides for antisense delivery
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
US11608491B2 (en) 2019-02-22 2023-03-21 Life Technologies Corporation Suspension system for adeno associated virus production
EP4005583A4 (en) * 2019-04-01 2023-04-26 Industry - University Cooperation Foundation Hanyang University CP2C TARGETING PEPTIDE ANTICANCER AGENT
KR102261371B1 (ko) * 2019-04-01 2021-06-08 한양대학교 산학협력단 CP2c 표적 펩티드 기반 항암제
EP4010028A1 (en) * 2019-08-05 2022-06-15 PolyPlus Transfection Compositions for transfecting a nucleic acid molecule into a cell comprising triazole compounds grafted to a cationic polymer, and their applications
KR102515464B1 (ko) * 2020-04-29 2023-03-28 연세대학교 원주산학협력단 핵산 또는 유전자 형질감염 효율을 개선하는 세포독성 완화 막 투과 펩타이드 및 이의 용도
CA3207656A1 (en) * 2021-02-08 2022-08-11 University Of British Columbia Anti-synucleinopathy peptide and methods to treat neurodegenerative diseases
TW202317147A (zh) 2021-07-08 2023-05-01 日商日本新藥股份有限公司 析出抑制劑
JPWO2023282345A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-07-08 2023-01-12
CN118201606A (zh) 2021-07-08 2024-06-14 日本新药株式会社 肾毒性减轻剂
CN113563429A (zh) * 2021-07-19 2021-10-29 天津大学 一种基于烷基化多肽的核酸递送系统及制备方法与应用
WO2023014909A1 (en) * 2021-08-04 2023-02-09 AJK Biopharmaceutical, LLC Amphiphilic peptides for nucleic acid and protein delivery
CN114106095B (zh) * 2021-11-11 2023-06-09 华南理工大学 基于聚集诱导发光原理的细胞自噬检测分子探针及其制备方法和应用
WO2023171804A1 (ja) 2022-03-10 2023-09-14 日本新薬株式会社 抗ウイルスアンチセンスオリゴマー
KR102717793B1 (ko) * 2022-05-26 2024-10-16 주식회사 바이오셀트란 신규한 미백 펩타이드 및 이를 함유하는 화장료 조성물
EP4547282A1 (en) 2022-06-30 2025-05-07 Life Technologies Corporation Lipid compositions for in vivo delivery
GB202211597D0 (en) 2022-08-09 2022-09-21 Nchain Licensing Ag Computer-implemented method and system
CN120615011A (zh) 2022-12-29 2025-09-09 生命科技股份有限公司 脂质组合物及用于递送到免疫细胞的方法
CN115947817B (zh) * 2023-02-22 2024-07-02 甘肃中肽生物科技有限公司 一种肿瘤相关多肽及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5316948A (en) 1992-09-04 1994-05-31 Life Technologies, Inc. N4 -methyl-2'-deoxycytidine 5'-triphosphate and its use in polymerase-catalyzed nucleic acid syntheses
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6075012A (en) 1994-02-11 2000-06-13 Life Technologies, Inc. Reagents for intracellular delivery of macromolecules
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
EP0874910A4 (en) 1995-06-07 1999-04-21 Life Technologies Inc ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
DE69937964T2 (de) 1998-11-12 2009-01-02 Invitrogen Corp., Carlsbad Transportreagentien
US6664040B2 (en) 2000-05-23 2003-12-16 The Regents Of The University Of California Compositions and methods for delivery of a molecule into a cell
PT1301213T (pt) * 2000-07-21 2017-04-19 Revance Therapeutics Inc Sistemas de transporte biológico de múltiplos componentes
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
GB0106315D0 (en) * 2001-03-14 2001-05-02 Ich Productions Ltd Transfection complexes
AU2004204456A1 (en) 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
JP4846588B2 (ja) 2003-05-22 2011-12-28 モレキュラー、トランスファー、インコーポレイテッド 核酸のトランスフェクションのための新規脂質
DK1653989T3 (da) * 2003-08-14 2009-11-23 Cellectis Antibakteriel sammensætning især mod gramnegative bakterier og som omfatter et peptid og et fortrinsvist hydrofobt antibakterielt middel
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
CA2633063A1 (en) 2005-12-16 2007-06-21 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids intocells
US20100061932A1 (en) 2005-12-30 2010-03-11 Evonik Roehm Gmbh Peptides useful as cell-penetrating peptides
JP5313867B2 (ja) 2006-03-30 2013-10-09 ドライス ファーマシューティカルズ，インコーポレイティド カンプトテシン−細胞透過性ペプチド複合体及びそれを含む医薬組成物
CA2960570C (en) 2006-05-05 2018-05-08 Molecular Transfer, Inc. Lipids for transfection of eukaryotic cells
JP5403681B2 (ja) 2007-03-07 2014-01-29 独立行政法人国立国際医療研究センター 新規核内移行ペプチド
AU2009329893A1 (en) * 2008-12-23 2011-06-30 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US9006415B2 (en) * 2010-04-06 2015-04-14 Massachusetts Institute Of Technology Targeted delivery of nucleic acids
CA2800741C (en) * 2010-05-30 2018-07-24 The Governing Council Of The University Of Toronto Mitochondrial penetrating peptides as carriers for anticancer compounds
NZ603732A (en) 2010-06-14 2015-02-27 Hoffmann La Roche Cell-penetrating peptides and uses therof
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
EP3470395A1 (en) 2010-11-15 2019-04-17 Life Technologies Corporation Amine-containing transfection reagents and methods for making and using same
CN102153629B (zh) * 2011-01-20 2013-07-24 华中科技大学 一种短肽及其应用
US8853145B2 (en) * 2011-11-14 2014-10-07 Carlos Witte-Hoffmann BLID; a novel protein domain for interaction with the Bcl-2 family of proteins
US20150266939A1 (en) 2012-03-15 2015-09-24 Permeon Biologics, Inc. Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use
EP3079723B1 (en) 2013-12-12 2020-05-27 Life Technologies Corporation Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
KR102476764B1 (ko) * 2015-12-23 2022-12-14 에스케이하이닉스 주식회사 소자분리구조 및 그 제조 방법
US9926825B2 (en) 2016-04-19 2018-03-27 GM Global Technology Operations LLC Method and apparatus for exhaust purification for an internal combustion engine

Also Published As

Publication number Publication date
EP3756690A3 (en) 2021-03-17
US20200392537A1 (en) 2020-12-17
AU2014361806B2 (en) 2019-12-19
AU2020202002A1 (en) 2020-04-09
CN113105559A (zh) 2021-07-13
WO2015089487A1 (en) 2015-06-18
US12152248B2 (en) 2024-11-26
US9856496B2 (en) 2018-01-02
EP3079723A1 (en) 2016-10-19
KR102532559B1 (ko) 2023-05-16
US10760098B2 (en) 2020-09-01
US20150211021A1 (en) 2015-07-30
ES2808866T3 (es) 2021-03-02
AU2014361806A1 (en) 2016-07-28
SG10201811729PA (en) 2019-02-27
JP6985347B2 (ja) 2021-12-22
BR112016013516A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-08-08
US20250109412A1 (en) 2025-04-03
EP3756690A2 (en) 2020-12-30
EP3079723B1 (en) 2020-05-27
US20180163231A1 (en) 2018-06-14
CN106456793A (zh) 2017-02-22
JP2020015747A (ja) 2020-01-30
US20250263751A1 (en) 2025-08-21
AU2020202002B2 (en) 2021-08-05
CA2933561A1 (en) 2015-06-18
KR20160103024A (ko) 2016-08-31
BR112016013516A8 (pt) 2020-05-19
CN106456793B (zh) 2021-04-30
JP6912887B2 (ja) 2021-08-04
JP2017500856A (ja) 2017-01-12

Similar Documents

Publication Publication Date Title
SG11201604697TA (en) Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
IL279395A (en) A vaccine
IL286759A (en) Therapeutic methods and preparations
GB2521022B (en) Compositions and methods
ZA201505966B (en) Peptides and compositions
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
RS59756B1 (sr) Kombinovana farmaceutska kompozicija
EP2953474A4 (en) COMPOSITIONS AND METHODS
EP2928562A4 (en) PEPTIDE THERAPEUTIC PRODUCTS AND METHODS OF USE
IL245470A0 (en) Methods and preparations for delayed immunotherapy
EP2968108A4 (en) COSMETIC COMPOSITIONS
GB201308072D0 (en) Compositions and methods
GB201309079D0 (en) Improved sweetner
IL233481A0 (en) Peptides and methods of using them
EP2914293A4 (en) METHOD OF USE OF FVIII POLYPEPTIDE
GB2511350B (en) Skincare compositions
GB201305813D0 (en) Compositions and methods
IL225985A0 (en) Preparation@cosmetic@mushkollal
GB201305556D0 (en) Skincare compositions
IL244537A0 (en) New administration preparations and methods of their use
ZA201600535B (en) Cosmetic composition
IL244956A0 (en) New peptide compositions
GB201319255D0 (en) Therapeutic compositions and methods
GB201216054D0 (en) Hair restoration
GB201322617D0 (en) Methods and compositions